Adjuvant β-lactam therapy combined with vancomycin for methicillin-resistantStaphylococcus aureus bacteremia: does β-lactam class matter?
Recommended Citation
Dilworth TJ, Casapao AM, Ibrahim OM, et al. Adjuvant β-Lactam Therapy Combined with Vancomycin for Methicillin-Resistant Bacteremia: Does β-Lactam Class Matter?. Antimicrob Agents Chemother. 2019;63(3). doi: 10.1128/AAC.02211-18.
Abstract
We analyzed the impact of vancomycin (VAN) combined with adjuvant β-lactam therapy (Combo) on persistent (≥5 days) methicillin-resistant Staphylococcus aureus bacteremia versus VAN alone by using pooled data from two previously published observational studies (n = 156). Combo was inversely associated with persistent bacteremia (adjusted odds ratio, 0.460; 95% confidence interval, 0.229 to 0.923). Acute kidney injury was more common with Combo than with VAN (18.9% and 7.6%, respectively; P = 0.062).
Document Type
Article
PubMed ID
30617094
